TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02188745
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Study: NCT02188745
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
Study: NCT02861716
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds.
Study: NCT02861716
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study: NCT01843920
Drug: Timolol-dorzolamide (Glaucoma drops)
Normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
Study: NCT00600366
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00118937
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
Study: NCT02327702
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: emtricitabine were given to each patients at baseline till 48 weeks after delivery
Study: NCT02625636
Drug: r-glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02419664
Drug: Gallium-68 DOTATOC PET
Normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
Study: NCT04508829
Drug: Anti-EGFR monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
Study: NCT03687554
Drug: Venglustat GZ/SAR402671
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Hard Capsule Route of administration: Oral
Study: NCT02158845
Drug: LNG-IUS: levonorgestrel intrauterine system
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
Study: NCT02158845
Drug: GnRHa: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprolide injected intramuscularly on a monthly basis
Study: NCT02858206
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
Study: NCT02858206
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
Study: NCT02858206
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
Study: NCT01662804
Drug: 3F8 Monoclonal Antibody Combined with Interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
Study: NCT04364035
Drug: GS-9620
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
Study: NCT00933634
Drug: propafenone
Normalized name: Propafenone
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
Study: NCT01782560
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
Study: NCT02161432
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose BI 187004 given as tablet in fed state
Study: NCT02161432
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose BI 187004 given as tablet in fasted state
Study: NCT02161432
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose BI 187004 given as oral solution
Study: NCT03152409
Drug: Aspirin 325mg
Normalized name: ASPIRIN 325MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
Study: NCT01224509
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
Study: NCT03652792
Drug: Azilsartan (Zhaoke)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan 20mg tablets from Zhaoke
Study: NCT03652792
Drug: Azilsartan (Takeda)
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilva 20mg tablets from Takeda
Study: NCT00538616
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
Study: NCT00538616
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
Study: NCT01064635
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: letrozole for 2-3 years after Tam
Study: NCT01064635
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole for 5 years after Tam
Study: NCT01666210
Drug: OTX-DP (Dexamethasone punctum plug)
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sustained and tapered release of dexamethasone from hydrogel punctum plug
Study: NCT04409132
Drug: Triferic
Normalized name: Triferic
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Study: NCT00768911
Drug: CT-322
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week
Study: NCT00768911
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met
Study: NCT00255034
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
Study: NCT04439253
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00255034
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
Study: NCT04625985
Drug: Metformin Glycinate
Normalized name: Glycine
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
Study: NCT02215447
Drug: NAB paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02215447
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02570815
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Study: NCT03167437
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
Study: NCT03167437
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
Study: NCT00877500
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03800602
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00571519
Drug: Rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablets administered orally, once daily
Study: NCT00571519
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg tablets administered orally, once daily
Study: NCT00571519
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg tablets administered orally, once daily
Study: NCT00571519
Drug: pioglitazone HCl
Normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg capsules administered orally, once daily
Study: NCT00571519
Drug: pioglitazone HCl
Normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg capsules administered orally, once daily
Study: NCT00571519
Drug: pioglitazone HCl 45 mg
Normalized name: pioglitazone HCl 45 mg ORAL TABLET
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg capsules administered orally, once daily
Study: NCT00571519
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets. Rescue medication.
Study: NCT00786097
Drug: Dermacyd PH_DETINLYN (Lactic Acid)
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134067
Drug: TAS-119
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134067
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
Study: NCT02713776
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
Study: NCT01305837
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg of methylprednisolone taken in 3 days every month
Study: NCT00865579
Drug: Safinamide
Normalized name: Safinamide
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning.
Study: NCT03874091
Drug: Morphine PCA pump
Normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine given postoperatively.
Study: NCT01596894
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Study: NCT00046488
Drug: IDEC-152
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
DrugBank: Lumiliximab (DB06162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
Study: NCT01261793
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
Study: NCT01261793
Drug: Epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Study: NCT04407442
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04407442
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT01445379
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
Study: NCT04116606
Drug: Active JNJ-54175446
Normalized name: Activated Charcoal
DrugBank: JNJ-54175446 (DB15358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
Study: NCT00520975
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00520975
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00363090
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00363090
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01711775
Drug: aleglitazar
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose Day 1, repeated oral dose once daily Days 5-14
Study: NCT01305551
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 5 mg, once on Day 1 only
Study: NCT01305551
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 500 mg, once on Day 1 only
Study: NCT01305551
Drug: Saxagliptin/Metformin XR FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 5/500 mg, once on Day 1 only
Study: NCT02316106
Drug: daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
Study: NCT02316106
Drug: daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
Study: NCT02316106
Drug: daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
Study: NCT04439136
Drug: Afatinib Dimaleate
Normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04120064
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
Study: NCT00213226
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04117477
Drug: Xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol dental wipes
Study: NCT02316821
Drug: RTA 402
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01298219
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mcg administered orally twice daily (BID)